Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas’ Xtandi Earns European Approval for HSPC
May 10, 2021
- Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players
April 30, 2021
- Shionogi, InveniAI Ink Drug Discovery Collaboration
April 30, 2021
- 300 Million Yen Fine Sought for Toho Too, Court Decision Due June 2: Bid-Rigging Trial
April 30, 2021
- Takeda’s Mobocertinib Gets FDA’s Priority Review for EGFR Exon 20-Mutant NSCLC
April 30, 2021
- Pfizer Japan Posts 251 Billion Yen Sales in FY2020 after Upjohn Spinoff
April 30, 2021
- Amgen Files KRAS Inhibitor Sotorasib in Japan for NSCLC
April 30, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Prosecutors Seek 300 Million Yen Fine for Suzuken, Jail Terms for Employees: Bid-Rigging Trial
April 28, 2021
- Takeda, Eisai, Chemiphar Ran Early Retirement Programs over Past Year: Survey
April 28, 2021
- Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
- Daiichi Sankyo Gets Brazil, South Korea Rights to Esperion’s Hypercholesterolemia Drug
April 28, 2021
- AbbVie Files Maviret for Use in Children Age 3 Plus
April 28, 2021
- Nihon Generic Recalling Metformin Products over Carcinogen Risks
April 27, 2021
- SymBio’s Brincidofovir Gets FDA’s Fast-Track Status
April 27, 2021
- Kyorin Grabs Distribution Rights to MSD’s Cough Medicine in Japan
April 27, 2021
- Lilly, Daiichi Sankyo Roll Out Migraine Drug Emgality in Japan
April 27, 2021
- Novartis Offering Voluntary Redundancy for 3rd Consecutive Year, Targets Sales & Medical across Therapeutic Areas
April 27, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…